MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/js9.0000000000002225

Медицинская библиотека · International journal of surgery (London, England) · 2025

Safety and clinical efficacy of neoadjuvant chemoradiation therapy with immunotherapy for organ preservation in ultra-low rectal cancer: preliminary results of the CHOICE-I trial: a prospective cohort study.

Zhou Leqi, Yu Guanyu, Shen Yuxin, Wen Rongbo, Ding Haibo, Zhou Jidian, Zhu Xiaoming, Hong Yonggang, Gong Haifeng, Liu Lianjie, Wang Hao, Zhang Huojun, Bai Chenguang, Hao Liqiang, Zhang Wei

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

OBJECTIVE

To explore the safety and efficacy of neoadjuvant chemoradiotherapy (nCRT) combined with a PD-1 antibody in improving complete clinical response (cCR) and organ preservation in patients with ultra-low rectal cancer.

METHODS

This was a prospective phase II, single-arm, open-label trial. Patients with confirmed pMMR status T 1-3a N 0-1 M 0 retcal adenocarcinoma were included. Long-course chemoradiotherapy was delivered to a dose of 50 Gy. A PD-1 antibody was added 2 weeks after the first radiotherapy session, and two courses were administered. After chemoradiotherapy, CapeOX plus PD-1 antibody was administered to patients for two cycles. After evaluation, patients with cCR were managed with a watch-and-wait (W&W) approach. Local excision or a W&W approach was performed for patients with near complete clinical response (ncCR) as per multidisciplinary team decision. Radical surgery was recommended for poorly regressed or progressed tumors.

RESULTS

Twenty-five patients were enrolled, but two patients withdrew from the study. A total of 23 patients completed the entire neoadjuvant therapy. Ten and five patients achieved cCR and ncCR, respectively, and the rest had a partial clinical response. Patients with cCR were managed with W&W. Four patients with ncCR underwent local excision and were managed using W&W. Eight patients with partial clinical response underwent anus-preserving surgery. At the last follow-up, the rectum and anus preservation rates were 63.4% (14/22) and 95.5% (21/22), respectively.

CONCLUSION

nCRT combined with immunotherapy tended to achieve better cCR and rectum preservation rates with good tolerance in patients.

Для цитирования: Zhou Leqi, Yu Guanyu, Shen Yuxin, Wen Rongbo, Ding Haibo, Zhou Jidian, Zhu Xiaoming, Hong Yonggang, Gong Haifeng, Liu Lianjie, Wang Hao, Zhang Huojun, Bai Chenguang, Hao Liqiang, Zhang Wei. Safety and clinical efficacy of neoadjuvant chemoradiation therapy with immunotherapy for organ preservation in ultra-low rectal cancer: preliminary results of the CHOICE-I trial: a prospective cohort study.. International journal of surgery (London, England). 2025. DOI: 10.1097/js9.0000000000002225.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.